DBV Technologies (NASDAQ:DBVT) Stock Price Down 9.1% – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price was down 9.1% during trading on Monday . The company traded as low as $17.49 and last traded at $17.3150. Approximately 71,626 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 207,616 shares. The stock had previously closed at $19.05.

Analyst Upgrades and Downgrades

DBVT has been the subject of several analyst reports. Guggenheim restated a “buy” rating and set a $51.00 price target (up previously from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.38.

DBV Technologies Price Performance

The stock has a market capitalization of $684.93 million, a price-to-earnings ratio of -3.29 and a beta of -1.17. The business’s fifty day moving average price is $16.04 and its 200-day moving average price is $12.59.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider directly owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This trade represents a 15.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in DBVT. Vivo Capital LLC purchased a new stake in shares of DBV Technologies during the second quarter valued at approximately $9,659,000. Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies in the second quarter worth $340,000. New York State Common Retirement Fund bought a new position in DBV Technologies in the 3rd quarter valued at $34,000. Artisan Partners Limited Partnership bought a new position in DBV Technologies in the 3rd quarter valued at $519,000. Finally, DLD Asset Management LP purchased a new stake in shares of DBV Technologies during the 3rd quarter valued at $250,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.